Table 4.

Significant risk factors for hemoptysis from the univariate and multivariate analyses (n = 104 assessment)

Patient baseline factor	Total patients	Case patients	Patient ratio	Conditional logistic regression analysis: (univariate)		Step‐wise logistic regression analysis: (multivariate)
				Odds ratio (95% CI)	P‐value	Odds ratio (95% CI)	P‐value
Prior therapy with anticoagulant, aspirin, NSAID, or antiplatelet drug
No	68	8	11.8
Yes	36	13	36.1	6.9541 (1.8493–26.1502)	0.0041	–	–
Prior thoracic radiotherapy
No	88	14	15.9
Yes	16	7	43.8	4.0201 (1.2285–13.1543)	0.0214	2.7666 (0.6154–12.4366)	0.1844
Concomitant therapy with anticoagulant, aspirin, NSAID, or antiplatelet drug
No	70	10	14.3
Yes	34	11	32.4	3.0451 (1.0354–8.9557)	0.0430	–	–
Concomitant thoracic radiotherapy
No	99	18	18.2
Yes	5	3	60.0	5.9999 (1.0025–35.9077)	0.0496	6.1904 (0.6336–60.4794)	0.1169
Central lesion
No	82	11	13.4
Yes	22	10	45.5	6.2076 (1.8882–20.4077)	0.0026	–	–
Tumor involvement of peripheral vessels
No	74	9	12.2
Yes	30	12	40.0	6.1545 (1.8720–20.2332)	0.0027	–	–
Tumor exposure in central airway down to segmental bronchi
No	82	11	13.4
Yes	22	10	45.5	6.2076 (1.8882–20.4077)	0.0026	5.2948 (1.2247–22.8901)	0.0256

NSAID, non‐steroidal anti‐inflammatory drug.